Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK signs agreement with the WHO to donate 50 million doses of pandemic H1N1 vaccine for distribution to developing countries
GSK today announced that it has signed an agreement with WHO to donate 50 million doses of its influenza vaccine.
-
Pandemic 2009 Influenza Update: Pandemrix™ data on co-administration with annual seasonal influenza vaccine (Fluarix®)
The trial involves 168 adults aged over 60 years of age, and was designed to evaluate the tolerability and immunogenicity.
-
GlaxoSmithKline and XenoPort announce extension of GSK1838262 (XP13512) FDA review date to 9 February 2010
GSK and XNPT today announced that FDA has extended the original PDUFA goal date for its review of NDA for GSK to February 9, 2010.
-
World Health Organization Grants Prequalification for Global Use to GSK’s 10-Valent Synflorix™ Vaccine
First prequalification for pneumococcal disease vaccine, a threatening disease affecting many children; follows first World Pneumonia Day.
-
World’s largest malaria vaccine trial now underway in seven African countries
Pivotal testing of RTS,S is on track for target enrollment of 16,000 children
-
ViiV Healthcare launches: A new specialist HIV company dedicated to delivering advances in HIV treatment and care
CEO promises 'relentless pursuit' of new treatments
-
Retigabine Regulatory Update
on 30 October, they filed a New Drug Application with the FDA and MAA with EMEA for retigabine.
-
GlaxoSmithKline and Human Genome Sciences announce positive results in second of two phase 3 trials of Benlysta in systemic lupus erythematosus
Benlysta 10 mg/kg plus standard of care met its primary efficacy endpoint by achieving a statistically significant improvement.
-
Results announcement for the third quarter 2009
See the quarterly results page for more information.
-
Pandemic 2009 Influenza Update: Pandemrix™ data in an elderly population
GlaxoSmithKline (GSK) today announced that this week, approximately half a million people will have received its pandemic H1N1 vaccine.
-
GlaxoSmithKline and Theravance commence Phase III Horizon programme to develop a next-generation treatment for COPD
GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the first patient has commenced treatment.
-
GSK and Genmab receive accelerated approval for Arzerra™
Today, GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced the accelerated approval of Arzerra TM (ofatumumab).
-
Pandemic (H1N1) 2009 Influenza Update: Experience of GSK’s H1N1 adjuvanted vaccine, Pandemrix™, and preliminary paediatric results
GSK today announced that, to date, more than 150,000 people have received GSK pandemic H1N1 vaccine, Pandemrix.
-
GlaxoSmithKline and Human Genome Sciences announce full presentation at ACR of positive phase 3 study results for Benlysta in systemic lupus erythematosus
Benlysta (belimumab) significantly reduced SLE disease activity, disease flare rates and fatigue; delayed time-to-first SLE disease flare.
-
FDA approves GlaxoSmithKline’s Votrient™ for advanced renal cell cancer
GSK announced that FDA has approved Votrient to treat patients with advanced renal cell carcinoma (RCC).
-
FDA approves Cervarix, GlaxoSmithKline’s cervical cancer vaccine
GSK announced today that FDA has approved Cervarix[Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant].
-
Pandemic (H1N1) 2009 Influenza Update: Results from second clinical trial of GSK’s H1N1 adjuvanted vaccine confirm immune response and tolerability
GSK announced results from a second clinical trial of its pandemic (H1N1) adjuvanted vaccine.
-
GSK’s Cervarix® becomes the first cervical cancer vaccine to gain approval in Japan
Landmark approval paves the way for access to the vaccine for women in Japan
-
GlaxoSmithKline and Prosensa form alliance to fight Duchenne Muscular Dystrophy
GlaxoSmithKline plc (GSK) announced today that it has entered into a unique partnership with the UK Government.
-
GSK partners with UK Government and Wellcome Trust to stimulate innovation through the creation of a world-class science park
GSK announced today the U.S. Food and Drug Administration (FDA) has not yet completed the review of the Biologics License Application.
